HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sarah Danson Selected Research

Melanoma (Melanoma, Malignant)

11/2023A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM).
1/2022Inconsistencies in Modeling the Efficacy of the Oncolytic Virus HSV1716 Reveal Potential Predictive Biomarkers for Tolerability.
7/2021The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma.
12/2020Effect of carboplatin when administered after dacarbazine failure: Clinical benefit of sequential therapy.
1/2018Genome-Wide Analysis of Circulating Cell-Free DNA Copy Number Detects Active Melanoma and Predicts Survival.
1/2018Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.
10/2015Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients.
12/2011Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mononuclear cells.
4/2009Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer.
1/2005Improving outcomes in advanced malignant melanoma: update on systemic therapy.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Sarah Danson Research Topics

Disease

19Neoplasms (Cancer)
01/2023 - 07/2002
11Melanoma (Melanoma, Malignant)
11/2023 - 07/2002
8Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
10/2022 - 05/2004
7Neoplasm Metastasis (Metastasis)
12/2020 - 10/2004
6Mesothelioma
06/2022 - 09/2013
5Disease Progression
10/2022 - 10/2015
5Lung Neoplasms (Lung Cancer)
10/2022 - 06/2005
5Malignant Mesothelioma
06/2022 - 09/2013
3Thrombocytopenia (Thrombopenia)
01/2023 - 04/2009
3Nausea
10/2022 - 01/2020
3Bone Resorption
10/2020 - 10/2004
3Breast Neoplasms (Breast Cancer)
09/2015 - 10/2002
2Neutropenia
01/2023 - 05/2019
2Fatigue
10/2022 - 01/2022
2Small Cell Lung Carcinoma (Small Cell Lung Cancer)
01/2022 - 01/2019
2Carcinoma (Carcinomatosis)
01/2021 - 08/2003
1Uveal melanoma
03/2024
1Colorectal Neoplasms (Colorectal Cancer)
11/2023
1Ovarian Neoplasms (Ovarian Cancer)
10/2022
1Dyspnea (Shortness of Breath)
10/2022
1Pleural Effusion (Pleural Effusions)
01/2022
1Vomiting
01/2022
1Anorexia
01/2022
1Pain (Aches)
12/2019
1Brain Neoplasms (Brain Tumor)
10/2015
1Primary Myelofibrosis (Myelosclerosis)
02/2015
1Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
04/2009
1Non-Hodgkin Lymphoma (Lymphosarcoma)
04/2009
1Lymphoma (Lymphomas)
04/2009

Drug/Important Bio-Agent (IBA)

6Cisplatin (Platino)FDA LinkGeneric
01/2021 - 08/2003
5PlatinumIBA
10/2022 - 08/2007
5Biomarkers (Surrogate Marker)IBA
01/2022 - 10/2004
3Paclitaxel (Taxol)FDA LinkGeneric
03/2024 - 05/2004
3DNA (Deoxyribonucleic Acid)IBA
10/2022 - 04/2005
3CytokinesIBA
01/2022 - 07/2002
3IpilimumabIBA
07/2021 - 10/2015
3GemcitabineFDA Link
01/2021 - 08/2003
3Carboplatin (JM8)FDA LinkGeneric
12/2020 - 08/2003
3ErbB Receptors (EGF Receptor)IBA
08/2007 - 01/2005
2Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
03/2024 - 01/2018
2olaparibIBA
10/2022 - 01/2022
2NivolumabIBA
11/2021 - 04/2018
2Monoclonal AntibodiesIBA
07/2021 - 01/2018
2MethyltransferasesIBA
01/2021 - 12/2011
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2018 - 09/2015
2Docetaxel (Taxotere)FDA Link
11/2014 - 04/2009
2Gefitinib (Iressa)FDA Link
08/2007 - 01/2005
2Mitomycin (Mitomycin-C)FDA LinkGeneric
04/2005 - 08/2003
1AZD 6244IBA
03/2024
1dabrafenibIBA
11/2023
1trametinibIBA
11/2023
1Cancer VaccinesIBA
11/2023
1SRA737IBA
01/2023
1Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA
10/2022
1Poly(ADP-ribose) Polymerase InhibitorsIBA
10/2022
1Vinorelbine (Navelbine)FDA LinkGeneric
06/2022
1Immunologic Factors (Immunomodulators)IBA
01/2022
1AntibodiesIBA
07/2021
1guadecitabineIBA
01/2021
1Dacarbazine (DIC)FDA LinkGeneric
12/2020
1NF-kappa B (NF-kB)IBA
10/2020
1LigandsIBA
10/2020
1Zoledronic Acid (Zometa)FDA Link
10/2020
1DenosumabFDA Link
10/2020
1fisetinIBA
07/2020
1QuercetinIBA
07/2020
1navitoclaxIBA
07/2020
1STA 9090IBA
01/2020
1Pemetrexed (MTA)FDA Link
01/2020
1Folic Acid AntagonistsIBA
01/2020
1Proteins (Proteins, Gene)FDA Link
01/2020
1collagen type I trimeric cross-linked peptideIBA
12/2019
1Analgesics (Analgesic Drugs)IBA
12/2019
1N-Methylaspartate (NMDA)IBA
12/2019
1saracatinibIBA
12/2019
1Glutamate Receptors (Glutamate Receptor)IBA
12/2019
1src-Family KinasesIBA
12/2019
1Radium-223IBA
05/2019
1AsbestosIBA
04/2018
1Bevacizumab (Avastin)FDA Link
01/2018
1Cell-Free Nucleic AcidsIBA
01/2018
1AlbuminsIBA
10/2015
1L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA
10/2015
1Methotrexate (Mexate)FDA LinkGeneric
02/2015
1Janus KinasesIBA
02/2015
1LY 2181308IBA
11/2014
1Antisense OligonucleotidesIBA
11/2014
1SurvivinIBA
11/2014
1Bortezomib (Velcade)FDA Link
09/2013
1SmokeIBA
12/2012
1Messenger RNA (mRNA)IBA
04/2009

Therapy/Procedure

13Therapeutics
06/2022 - 01/2005
11Drug Therapy (Chemotherapy)
10/2022 - 01/2005
5Immunotherapy
01/2023 - 07/2002
1Adjuvant Chemotherapy
11/2023
1Resistance Training
01/2023
1Chemoradiotherapy
01/2022
1Oncolytic Virotherapy
01/2022
1Neoadjuvant Therapy
01/2021
1Palliative Care (Palliative Therapy)
01/2012